Clinical Scorecard: Clinical Value of White Blood Cell–Based Inflammatory Markers in Children With Systemic Lupus Erythematosus
At a Glance
Category
Detail
Condition
Childhood-onset systemic lupus erythematosus (cSLE), a chronic autoimmune disorder with multisystem involvement.
Key Mechanisms
Dysregulated innate and adaptive immunity leads to autoantibody production and immune-complex deposition; WBC-IP assess immune-cell activation and morphologic changes using CBC-derived signals.
Target Population
Children younger than 18 years with SLE classified under at least one of the 1997 ACR, 2012 SLICC, or 2019 EULAR/ACR criteria.
Care Setting
Prospective pediatric rheumatology cohort at a hospital, using routine clinical assessments and blood specimens; participants with recent infection were excluded.
Key Highlights
The study examined associations between WBC-IP and cSLE disease activity and compared their diagnostic performance with conventional inflammatory markers.
WBC-IP are derived from automated hematology analyzer signals and include measures of neutrophil and lymphocyte activation and morphology.
NEUT-RI and NEUT-GI assess neutrophil reactivity and granularity; RE-LYMP, AS-LYMP, and LY-WX, LY-WY, and LY-WZ assess lymphocyte features.
IG% is not classified as an extended inflammation parameter but may indicate early neutrophil release from bone marrow during inflammatory responses.
The supplied article text describes the study rationale and methods but does not provide results or conclusions about marker performance.
Guideline-Based Recommendations
Diagnosis
Study eligibility required SLE classification under at least one of the 1997 ACR, 2012 SLICC, or 2019 EULAR/ACR criteria.
Management
The supplied excerpt does not provide treatment recommendations.
Monitoring & Follow-up
The study assessed disease activity using SLEDAI-2K; inactive disease was defined as cSLEDAI-2K of 0, regardless of treatment.
Risks
The article states that cSLE generally has more severe clinical features, higher disease activity scores, and greater risk of long-term organ damage than adult-onset SLE.
The article notes that ESR, CRP, and PCT may be affected by anemia, infection, and glucocorticoid use; complement and anti-dsDNA changes may trail clinical activity.
Patient & Prescribing Data
Prospective cohort of patients younger than 18 years with classified SLE, enrolled at Ramathibodi Hospital from May 2021 through March 2023; recent infection within two weeks was an exclusion criterion.
The excerpt provides no prescribing comparison or treatment-effect results. Study-defined remission allowed ongoing antimalarial or immunosuppressive therapy and limited prednisolone to 5 mg/day or 0.15 mg/kg/day.
Clinical Best Practices
The study compared WBC-IP with conventional inflammatory markers in relation to cSLE disease activity; the supplied excerpt does not report results or establish clinical recommendations.
